Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $24 | $24 | $13 | $7 |
| Gross Profit | -$24 | -$24 | -$13 | -$7 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,626 | $5,271 | $10,514 | $7,187 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,612 | $5,920 | $5,249 | $5,735 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$358 | -$1,165 | $0 |
| Operating Expenses | $13,238 | $10,832 | $14,598 | $12,922 |
| Operating Income | -$13,261 | -$10,832 | -$14,598 | -$12,929 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,331 | $917 | $919 | $796 |
| Pre-Tax Income | -$11,930 | -$9,916 | -$13,679 | -$12,133 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,930 | -$9,916 | -$13,679 | -$12,133 |
| % Margin | – | – | – | – |
| EPS | -0.133 | -0.11 | -0.15 | -0.17 |
| % Growth | -20.5% | 26.7% | 11.8% | – |
| EPS Diluted | -0.133 | -0.11 | -0.15 | -0.17 |
| Weighted Avg Shares Out | 90,051 | 90,010 | 89,537 | 69,362 |
| Weighted Avg Shares Out Dil | 90,051 | 90,010 | 89,537 | 69,362 |
| Supplemental Information | – | – | – | – |
| Interest Income | $838 | $917 | $919 | $796 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $24 | $24 | $13 | $7 |
| EBITDA | -$11,907 | -$11,167 | -$15,750 | -$12,126 |
| % Margin | – | – | – | – |